Evidence map›Paper›PMID 40022059›Full record

ArticleRespiratory research2025

Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry.

Aparna C Swaminathan, Jeremy M Weber, Jamie L Todd, Scott M Palmer, Megan L Neely, Timothy P Whelan, Grace Hyun J Kim, Thomas B Leonard, Jonathan Goldin

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01915511 (Idiopathic Pulmonary Fibrosis Prospective Outcomes), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01915511 recruitingnot on this map

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry

Typeobservational_patient_registrySponsorDuke UniversityRan2014 to 2031Enrolled3,000ConditionsIdiopathic Pulmonary Fibrosis, Interstitial Lung Disease
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Progressive pulmonary fibrosis.European radiology · 2026
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aparna C SwaminathanDuke Clinical Research Institute, Durham, NC, USA. aparna.swaminathan@dm.duke.edu.
Jeremy M WeberDuke Clinical Research Institute, Durham, NC, USA.
Jamie L ToddDuke Clinical Research Institute, Durham, NC, USA.
Scott M PalmerDuke Clinical Research Institute, Durham, NC, USA.
Megan L NeelyDuke Clinical Research Institute, Durham, NC, USA.
Timothy P WhelanDepartment of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Medical University of South Carolina, Charleston, SC, USA.
Grace Hyun J KimDepartment of Radiological Sciences, David Geffen School of Medicine, Department of Biostatistics, Fielding School of Public Health, University of California Los Angeles, Los Angeles, USA.
Thomas B LeonardBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.
Jonathan GoldinDepartments of Radiology and Medicine, University of California Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic value of patterns and quantitative measures of lung fibrosis on high-resolution computed tomography (HRCT) in patients identified as having progressive pulmonary fibrosis (PPF) has not been established. We investigated whether HRCT patterns and quantitative scores were associated with risk of progression in patients with PPF.

methodsPatients enrolled in the ILD-PRO Registry had an interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis, reticular abnormality and traction bronchiectasis, and met criteria for ILD progression. HRCT images taken between 24 months prior to enrollment and 90 days after enrollment were analyzed using a machine learning algorithm to derive quantitative scores. Associations were assessed between HRCT pattern (usual interstitial pneumonia [UIP]-like versus other patterns) and tertiles of quantitative scores and measures of disease severity at enrollment, and between these patterns/tertiles at enrollment and ILD progression (relative decline in forced vital capacity [FVC] % predicted ≥ 10%, lung transplant, or death) over a median follow-up of 17.3 months.

resultsAmong 395 patients, 178 (45.1%) had a UIP-like pattern on HRCT. A UIP-like pattern did not associate with worse disease severity at enrollment or an increased risk of ILD progression (HR 1.01 [95% CI: 0.71, 1.44]). The highest quantitative lung fibrosis (QLF) score tertile (≥ 20.5%) was associated with worse disease severity. In unadjusted analyses, patients with QLF scores in the highest tertile had a significantly increased risk of ILD progression versus the middle tertile (HR [95% CI] 1.63 [1.07, 2.49] and a numerically increased risk versus the lowest tertile (HR 1.46 [0.97, 2.18]); however, after adjustment for sex, age, FVC % predicted and oxygen use at enrollment, there were no significant differences. There were no significant associations between tertiles of quantitative ILD score, quantitative ground glass score, or quantitative honeycomb cysts score and risk of ILD progression in unadjusted or adjusted analyses.

conclusionsIn a real-world cohort of patients with PPF, QLF score associated with subsequent risk of ILD progression, while HRCT pattern did not. The QLF score did not provide additional prognostic information beyond clinical variables.

trial registrationClinicalTrials.gov; No: NCT01915511; registered August 5, 2013; URL: www. CLINICALTRIALS: gov .

Indexed as

Idiopathic Pulmonary FibrosisLung Diseases, InterstitialPulmonary FibrosisRegistriesTomography, X-Ray ComputedAgedDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisDisease progressionInterstitial lung disease

Identifiers

PMID40022059
PMCPMC11871617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.